Printer Friendly

IMMUNOMEDICS RELEASES FIRST QUARTER EARNINGS; PROJECTS PROMISING RESULTS FOR 1992 AT ANNUAL MEETING

           IMMUNOMEDICS RELEASES FIRST QUARTER EARNINGS;
     PROJECTS PROMISING RESULTS FOR 1992 AT ANNUAL MEETING
    WARREN, N.J., Nov. 7 /PRNewswire/ -- At today's annual meeting of Immunomedics' (NASDAQ: IMMU) shareholders, chairman of the board, Dr. David M. Goldberg, remarked that "the past year was very successful for our company on all fronts -- fiscal, scientific, clinical, patents and overall corporate development."  Russell C. McLauchlan, president, expanded by listing certain accomplishments as "the filing of a product license application with the U.S. Food and Drug Administration for the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA, forming a relationship with Adria Laboratories for marketing in North America, raising $20 million in capital, and advancing the company's worldwide clinical trial program.  Last year was one of outstanding progress for Immunomedics, and I foresee an equally promising performance in 1992 as our products progress towards commercialization," stated McLauchlan.
    The company's goals for 1992 include filing with the Committee of Proprietary Medicinal Products for the approval to market ImmuRAID-CEA in Europe, expanding corporate alliances for the company's imaging products, and building a commercial scale manufacturing facility.
    The company also announced that revenues for the first quarter ended Sept. 30, 1991 were $5,616,000, as compared to $367,500 for the same period last year.  This includes the payment of $5 million received from Adria Laboratories, the first of a series of milestone payments provided by this arrangement.
    Amy Factor, vice president, finance and administration, commented, "As of Sept. 30, 1991, working capital was $25.4 million, an increase of over $20 million from the fiscal year ending June 30, 1991. Immunomedics has significantly strengthened its cash position and has the financial ability to realize the objectives established for the coming year.  We are now making the transition from an R&D-focused company moving towards product commercialization."
    Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases.  Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
                         IMMUNOMEDICS, INC.
                       Condensed Balance Sheets
      Periods ended               Sept. 30, 1991      June 30, 1991
                                    (Unaudited)
    Assets:
     Current assets                 $30,944,204         $10,732,538
     Property & equipment-net         1,339,313           1,350,838
     Other assets                        58,783              61,522
     Total assets                    32,342,300          12,144,898
    Liabilities & Shareholders' Equity:
     Current liabilities              5,618,584           5,392,579
     Long-term debt                     329,991             376,092
     Shareholders' equity            26,393,725           6,376,227
     Total liabilities &
      shareholders' equity           32,342,300          12,144,898
                            IMMUNOMEDICS, INC.
                           Summary of Operations
                                (Unaudited)
      Three months ended Sept. 30:       1991                1990
    Revenues                         $5,601,866            $367,500
    Costs & expenses                  1,995,674           1,740,009
    Net income (loss)                 3,606,192          (1,372,509)
    Primary earnings (loss)
     per common share                      $.13               ($.06)
    -0-         11/7/91
    /CONTACT:  Amy Factor of Immunomedics, 908-647-5400/
    (IMMU) CO:  Immunomedics, Inc. ST:  New Jersey IN:  MTC SU:  ERN TS-JT -- NY044 -- 2189 11/07/91 11:56 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:510
Previous Article:IRT PROPERTY CONTRACTS TO PURCHASE SHOPPING CENTER
Next Article:ALEXANDER & ALEXANDER SERVICES, ALEXANDER & ALEXANDER EUROPE AND REED STENHOUSE COMPANIES DECLARE REGULAR QUARTERLY DIVIDENDS
Topics:


Related Articles
IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
IMMUNOMEDICS REPORTS RESULTS OF OPERATIONS AND SIGNIFICANT INCREASE IN WORKING CAPITAL
POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
IMMUNOMEDICS REPORTS FISCAL 1992 FINANCIAL RESULTS
IMMUNOMEDICS ANNOUNCES THIRD QUARTER 1993 FINANCIAL RESULTS IN LINE WITH COMPANY EXPECTATIONS
IMMUNOMEDICS TO RESEARCH CANCER VACCINE UNDER FEDERAL GRANT
Immunomedics, Inc. Reports Third Quarter Results
Immunomedics Invents New Vaccine Technology For Cancer And Infectious Diseases.
Immunomedics Reports First Quarter 2000 Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters